EUVIMEDEUVIMED entdecken
Crossref

Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis

Chanhyeok Jeon, Yurin Jang, Seung Hoon Lee, Subin Weon, Hyosun Park, Suein Lee, Younseo Oh, Sung Hoon Choi, Sung Eun Wang, Tae-Hwan Kim, Il-Hoon Sung, Sungsin Jo

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Chanhyeok Jeon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul 04763, Republic of Korea; Deparment of Translational Medici…. Hauptthemen laut MEDLINE: Kynurenine, Spondylitis, Ankylosing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Ankylosing spondylitis (AS) exhibits paradoxical bone features typically characterized by new bone formation and systemic bone loss. Although abnormal kynurenine (Kyn), a tryptophan metabolite, has been closely linked to the disease activity of AS, the distinct role of its pathological bone features remains unknown. METHODS: Kynurenine sera level was collected from healthy control (HC; n = 22) and AS (n = 87) patients and measured by ELISA. In the AS group, we analyzed and compared the Kyn level based on the modified stoke ankylosing spondylitis spinal score (mSASSS), MMP13, and OCN. Under osteoblast differentiation, the treatment with Kyn in AS-osteoprogenitors conducted cell proliferation, alkaline phosphatase activity, bone mineralization-related alizarin red s (ARS), von kossa (VON), hydroxyapatite (HA) staining, and mRNA expression markers (ALP, RUNX2, OCN, and OPG) for bone formation. TRAP and F-actin staining was used for osteoclast formation of mouse osteoclast precursors. RESULTS: Kyn sera level was significantly elevated in the AS group compared to the HC. In addition, Kyn sera level was correlated with mSASSS (r = 0.03888, p = 0.067), MMP13 (r = 0.0327, p = 0.093), and OCN (r = 0.0436, p = 0.052). During osteoblast differentiation, treatment with Kyn exhibited no difference in cell proliferation and alkaline phosphate (ALP) activity for bone matrix maturation but promoted ARS, VON, and HA staining for bone mineralization. Interestingly, osteoprotegerin (OPG) and OCN expressions of AS-osteoprogenitors were augmented in the Kyn treatment during differentiation. In growth medium, Kyn treatment of AS-osteoprogenitors resulted in induction of OPG mRNA, protein expression, and Kyn-response genes (AhRR, CYP1b1, and TIPARP). Secreted OPG proteins were observed in the supernatant of AS-osteoprogenitors treated with Kyn. Notably, the supernatant of Kyn-treated AS-osteoprogenitors interrupted the RANKL-mediated osteoclastogenesis of mouse osteoclast precursor such as TRAP-positive osteoclast formation, NFATc1 expression, and osteoclast differentiation markers. CONCLUSION: Our results revealed that elevated Kyn level increased the bone mineralization of osteoblast differentiation in AS and decreased RANKL-mediated osteoclast differentiation by inducing OPG expression. Out study have implication for potential coupling factors linking osteoclast and osteoblast where abnormal Kyn level could be involved in pathological bone features of AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KynurenineSpondylitis, AnkylosingAnimalsMiceMatrix Metalloproteinase 13OsteoblastsGene Expression RegulationOsteoclastsOsteoprotegerinCell DifferentiationRNA, MessengerRANK Ligand

Stichwörter der Autor:innen

Ankylosing spondylitisKynurenineOsteoblastsOsteoclastsOsteoprotegerin

Substanzen

KynurenineMatrix Metalloproteinase 13OsteoprotegerinRNA, MessengerRANK Ligand

Autor:innen und Institutionen

  • Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul 04763, Republic of Korea; Deparment of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang Uni…
  • Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul 04763, Republic of Korea.
  • Hanyang University College of Medicine, Hanyang University, Seoul 04763, Republic of Korea.
  • Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul 04763, Republic of Korea; Department of Bioresearch, Huonslab, Seongnam-si, Gyeonggi-do 13201, Republic of Korea.
  • Hanyang University College of Medicine, Hanyang University, Seoul 04763, Republic of Korea; Department of Orthopedic Surgery, Hanyang University Hospital, Seoul 04763, Republic of Korea.
  • Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, United States.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Jeon, C., Jang, Y., Lee, S. H., Weon, S., Park, H., Lee, S., Oh, Y., Choi, S. H., Wang, S. E., Kim, T. H., Sung, I. H., & Jo, S. (2023). Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110132

Vancouver

Jeon C, Jang Y, Lee SH, Weon S, Park H, Lee S, et al. Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110132

BibTeX
@article{Jeon2023,
  author = {Jeon, Chanhyeok and Jang, Yurin and Lee, Seung Hoon and Weon, Subin and Park, Hyosun and Lee, Suein and Oh, Younseo and Choi, Sung Hoon and Wang, Sung Eun and Kim, Tae-Hwan and Sung, Il-Hoon and Jo, Sungsin},
  title = {Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110132}
}
Kostenlos starten →